JP2010528002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528002A5 JP2010528002A5 JP2010509325A JP2010509325A JP2010528002A5 JP 2010528002 A5 JP2010528002 A5 JP 2010528002A5 JP 2010509325 A JP2010509325 A JP 2010509325A JP 2010509325 A JP2010509325 A JP 2010509325A JP 2010528002 A5 JP2010528002 A5 JP 2010528002A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- therapeutic agent
- sost
- bone
- fab fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000988 bone and bone Anatomy 0.000 claims description 15
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims description 10
- 230000011164 ossification Effects 0.000 claims description 10
- 101150098533 SOST gene Proteins 0.000 claims description 9
- 102100034201 Sclerostin Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 6
- 230000008468 bone growth Effects 0.000 claims description 5
- 206010017076 Fracture Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 208000010392 Bone Fractures Diseases 0.000 claims description 3
- 230000000399 orthopedic effect Effects 0.000 claims description 3
- 230000003239 periodontal effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 102000058171 human SOST Human genes 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 102000019307 Sclerostin Human genes 0.000 description 6
- 108050006698 Sclerostin Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 108010043958 Peptoids Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 208000029725 Metabolic bone disease Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010049811 Extraskeletal ossification Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000034970 Heterotopic Ossification Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101100421899 Mus musculus Sost gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009469 Ossification of Posterior Longitudinal Ligament Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004446 longitudinal ligament Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88264206P | 2006-12-29 | 2006-12-29 | |
| PCT/US2007/088542 WO2009131553A2 (en) | 2006-12-29 | 2007-12-21 | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013255627A Division JP2014074046A (ja) | 2006-12-29 | 2013-12-11 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528002A JP2010528002A (ja) | 2010-08-19 |
| JP2010528002A5 true JP2010528002A5 (enExample) | 2014-03-06 |
Family
ID=39584303
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509325A Withdrawn JP2010528002A (ja) | 2006-12-29 | 2007-12-21 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2013255627A Withdrawn JP2014074046A (ja) | 2006-12-29 | 2013-12-11 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2016161654A Withdrawn JP2017014263A (ja) | 2006-12-29 | 2016-08-22 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2018179643A Pending JP2018199725A (ja) | 2006-12-29 | 2018-09-26 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013255627A Withdrawn JP2014074046A (ja) | 2006-12-29 | 2013-12-11 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2016161654A Withdrawn JP2017014263A (ja) | 2006-12-29 | 2016-08-22 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2018179643A Pending JP2018199725A (ja) | 2006-12-29 | 2018-09-26 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (9) | US8178099B2 (enExample) |
| EP (3) | EP2144613B1 (enExample) |
| JP (4) | JP2010528002A (enExample) |
| DK (1) | DK3345607T3 (enExample) |
| ES (2) | ES2930183T3 (enExample) |
| FI (1) | FI3345607T3 (enExample) |
| HU (1) | HUE060822T2 (enExample) |
| LT (1) | LT3345607T (enExample) |
| PL (1) | PL3345607T3 (enExample) |
| PT (1) | PT3345607T (enExample) |
| SI (1) | SI3345607T1 (enExample) |
| WO (1) | WO2009131553A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69942782D1 (de) | 1998-11-27 | 2010-10-28 | Ucb Sa | Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung |
| US7585501B2 (en) * | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| EP1636270B1 (en) | 2003-06-16 | 2016-07-20 | UCB Pharma S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| CA2578113A1 (en) | 2004-08-30 | 2006-03-09 | Spineovations, Inc. | Method of treating spinal internal disk derangement |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| US8178099B2 (en) | 2006-12-29 | 2012-05-15 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| AU2008330125B2 (en) | 2007-11-21 | 2012-11-22 | Amgen Inc. | Wise binding antibodies and epitopes |
| US8469961B2 (en) * | 2008-03-05 | 2013-06-25 | Neville Alleyne | Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints |
| WO2010115932A1 (en) * | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| US20130138221A1 (en) * | 2010-04-16 | 2013-05-30 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
| JP2014511842A (ja) | 2011-03-25 | 2014-05-19 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体結晶およびその製剤 |
| DK2739311T3 (en) | 2011-08-04 | 2018-04-23 | Amgen Inc | Method of treating bone slit defects |
| EA036740B1 (ru) | 2011-12-28 | 2020-12-15 | Эмджен Инк. | Способ увеличения высоты альвеолярного отростка посредством применения антител к склеростину |
| WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9770415B2 (en) * | 2012-11-27 | 2017-09-26 | Southwest Research Institute | Delivery substrates from aligned polymer biomaterials for tissue repair |
| JP2016510411A (ja) * | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| KR102024447B1 (ko) | 2015-01-16 | 2019-11-14 | 스파인오베이션즈, 인크. | 척추 디스크를 치료하기 위한 작용제 및 작용제를 포함하는 의료 키트 |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN106202901A (zh) * | 2016-07-04 | 2016-12-07 | 奥美之路(北京)健康科技股份有限公司 | 骨龄远程在线判读系统 |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| WO2019154410A1 (zh) * | 2018-02-12 | 2019-08-15 | 翼高生物科技有限公司 | 针对骨硬化蛋白的适体及其用途 |
| CN119241705A (zh) | 2018-03-30 | 2025-01-03 | 安姆根有限公司 | C末端抗体变体 |
| EP3920929A4 (en) * | 2019-02-04 | 2023-02-22 | Emory University | SCLEROSTIN INHIBITORS TO PROMOTE BONE MORPHOGENETIC PROTEIN EXPRESSION |
| EP4000633A4 (en) * | 2019-07-12 | 2024-02-21 | Kyoto University | NEUTRALIZING ANTIBODIES FOR THE TREATMENT OF DENTAL REGENERATION TARGETING THE USAG-1 MOLECULE |
| CN111658821A (zh) * | 2020-06-03 | 2020-09-15 | 深圳市百吉因生物科技有限公司 | 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用 |
| KR20260021016A (ko) | 2023-06-02 | 2026-02-12 | 33 메디칼, 인크. | 추간판성 통증의 치료를 위한 조성물, 및 그의 제조 및 사용 방법 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981002911A1 (en) | 1980-04-07 | 1981-10-15 | J Berman | Window shade roller assembly |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE114473T1 (de) * | 1984-04-30 | 1994-12-15 | Procter & Gamble | Ausrüstung für die verwendung bei der behandlung von osteoporose. |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4631211A (en) * | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5344654A (en) * | 1988-04-08 | 1994-09-06 | Stryker Corporation | Prosthetic devices having enhanced osteogenic properties |
| US5324819A (en) | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5298852A (en) * | 1988-12-22 | 1994-03-29 | Robert Bosch Gmbh | Arrangement for and method of controlling a three-phase-generator in a vehicle |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5561173A (en) * | 1990-06-19 | 1996-10-01 | Carolyn M. Dry | Self-repairing, reinforced matrix materials |
| KR100240308B1 (ko) | 1991-03-06 | 2000-01-15 | 플레믹 크리스티안 | 인간화된단클론성항체및혼성단클론성항체 |
| US5656593A (en) | 1991-03-11 | 1997-08-12 | Creative Biomolecules, Inc. | Morphogen induced periodontal tissue regeneration |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| NZ249677A (en) | 1992-02-19 | 1996-08-27 | Schering Corp | Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| CA2151486A1 (en) * | 1993-01-12 | 1994-07-21 | Arthur J. Ammann | Tgf-beta formulation for inducing bone growth |
| TW303299B (enExample) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US5550134A (en) * | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
| DE19647853A1 (de) * | 1996-11-19 | 1998-05-20 | Bioph Biotech Entw Pharm Gmbh | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität |
| US5939039A (en) | 1997-01-16 | 1999-08-17 | Orthovita, Inc. | Methods for production of calcium phosphate |
| JP4388602B2 (ja) * | 1997-02-07 | 2009-12-24 | ストライカー コーポレイション | マトリクスを含まない骨形成デバイス、移植片、およびその使用方法 |
| US20020098222A1 (en) * | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
| US7041641B2 (en) * | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| DE69818456T2 (de) * | 1997-04-22 | 2004-07-29 | Washington Research Foundation, Seattle | Knochentransplantate und -prothesen beschichtet mit tartratbeständiger säurephosphatase |
| US6025538A (en) | 1998-11-20 | 2000-02-15 | Musculoskeletal Transplant Foundation | Compound bone structure fabricated from allograft tissue |
| DE69942782D1 (de) | 1998-11-27 | 2010-10-28 | Ucb Sa | Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US6756480B2 (en) * | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| US20030082233A1 (en) * | 2000-12-01 | 2003-05-01 | Lyons Karen M. | Method and composition for modulating bone growth |
| WO2002067978A1 (en) * | 2001-02-23 | 2002-09-06 | Wyeth | Chondrogenic potential of human bone marrow-derived cd105+ cells by bmp |
| US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| BR0209564A (pt) | 2001-05-11 | 2004-10-26 | Wyeth Corp | Animal transgênico, embrião, camundongo transgênico, modelo animal para o estudo da modulação da densidade óssea, célula isolada, ácido nucleico para marcar o gene pela recombinação homóloga, e, métodos para estudar determinantes da massa óssea, para estudar moduladores de massa óssea, para estudar a massa óssea, para estudar um efeito hbm sobre os distúrbios ósseos, para identificar marcadores substitutos da formação/reabsorção ósseas, para estudar efeitos de hbm sobre os distúrbios cardìacos, para avaliar tratamentos cárdio-protetores quanto aos efeitos de modulação da massa óssea, para modular a densidade óssea, para produzir um camundongo transgênico e para identificar genes associados com a massa óssea |
| TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| MY143582A (en) * | 2001-06-26 | 2011-05-31 | Amgent Fremont Inc | Antibodies to opgl |
| CN100515504C (zh) | 2001-10-12 | 2009-07-22 | 美国英佛曼公司 | 涂层,涂布体及其制造方法 |
| EP1446114A4 (en) * | 2001-11-08 | 2005-05-25 | Merck & Co Inc | COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS |
| JP2005525312A (ja) * | 2002-01-10 | 2005-08-25 | オステオトロフィン エルエルシー | 骨同化物質を用いた骨疾患の治療方法 |
| JP2005519067A (ja) * | 2002-01-17 | 2005-06-30 | ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | トロンビンペプチド誘導体を用いた骨成長および軟骨形成の刺激 |
| JP3646167B2 (ja) * | 2002-02-19 | 2005-05-11 | 独立行政法人産業技術総合研究所 | フォスフォフォリンを含む複合生体材料 |
| US7332276B2 (en) * | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
| US7166133B2 (en) * | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
| WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| US20040002770A1 (en) | 2002-06-28 | 2004-01-01 | King Richard S. | Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof |
| US20060246060A1 (en) * | 2002-07-02 | 2006-11-02 | Nesta Douglas P | Novel stable formulation |
| US20040023322A1 (en) * | 2002-08-01 | 2004-02-05 | Goodheart Clyde R. | Method of producing non-recombinant BMP-2 and use thereof |
| KR20040023356A (ko) | 2002-09-11 | 2004-03-18 | 현대모비스 주식회사 | 파킹브레이크 작동시 출발제한 시스템 및 그 방법 |
| US7374776B2 (en) | 2002-09-30 | 2008-05-20 | Regen Biotech, Inc. | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers |
| JP3851602B2 (ja) * | 2002-10-02 | 2006-11-29 | ペンタックス株式会社 | 骨形成治療デバイス |
| JP2007525953A (ja) | 2003-06-06 | 2007-09-13 | ワイス | 骨リモデリングを調節する物質を同定するための方法および材料、ならびにそれによって同定された物質 |
| EP1636270B1 (en) | 2003-06-16 | 2016-07-20 | UCB Pharma S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US7943393B2 (en) | 2003-07-14 | 2011-05-17 | Phynexus, Inc. | Method and device for extracting an analyte |
| US6976816B2 (en) | 2003-08-01 | 2005-12-20 | Dana Corporation | Combination lock washer and spindle bearing assembly |
| MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| WO2005070439A1 (en) * | 2004-01-09 | 2005-08-04 | Regeneration Technologies Inc. | Implant comprising a human muscle tissue matrix |
| US7189263B2 (en) | 2004-02-03 | 2007-03-13 | Vita Special Purpose Corporation | Biocompatible bone graft material |
| US7531518B2 (en) * | 2004-05-14 | 2009-05-12 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US7648965B2 (en) * | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| WO2005118636A2 (en) * | 2004-05-27 | 2005-12-15 | Acceleron Pharma Inc. | Tgf derepressors and uses related thereto |
| MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| US8337873B2 (en) * | 2004-10-22 | 2012-12-25 | The Board Of Trustees Of The University Of Illinois | Hollow and porous orthopaedic or dental implant that delivers a biological agent |
| ES2902872T3 (es) * | 2005-01-06 | 2022-03-30 | Kuros Biosurgery Ag | Matrices suplementadas para la reparación de fracturas óseas |
| US7531533B2 (en) * | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| US8071574B2 (en) | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| US20060198863A1 (en) | 2005-03-03 | 2006-09-07 | Musculoskeletal Transplant Foundation | Ceramic composition for filling bone defects |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| JP2006320442A (ja) | 2005-05-18 | 2006-11-30 | Toshiba Ceramics Co Ltd | リン酸カルシウム系骨補填材 |
| US20060293667A1 (en) * | 2005-05-19 | 2006-12-28 | Agnes Vignery | Bone implant device and methods of using same |
| WO2006135734A2 (en) | 2005-06-10 | 2006-12-21 | The Regents Of The University Of California | Compositions and methods for altering bone density and bone patterning |
| CN101287761A (zh) * | 2005-06-15 | 2008-10-15 | 先灵公司 | 抗-igf1r抗体制剂 |
| WO2007030616A2 (en) | 2005-09-09 | 2007-03-15 | Wright Medical Technology, Inc. | Composite bone graft substitute cement and articles produced therefrom |
| KR20080084808A (ko) | 2005-11-17 | 2008-09-19 | 바이오미메틱 세라퓨틱스, 인크. | ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강 |
| US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
| CN101378782A (zh) * | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| WO2008133722A2 (en) | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| US8178099B2 (en) | 2006-12-29 | 2012-05-15 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CN101663043B (zh) | 2007-04-27 | 2014-03-12 | 尤尼基因实验室公司 | 促进和保持骨生长的方法和组合物 |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JP6511233B2 (ja) | 2014-08-28 | 2019-05-15 | 株式会社竹中工務店 | 柱脚部と鉄骨梁との接合構造 |
-
2007
- 2007-12-21 US US11/962,522 patent/US8178099B2/en active Active
- 2007-12-21 FI FIEP18157578.8T patent/FI3345607T3/fi active
- 2007-12-21 EP EP07875255.7A patent/EP2144613B1/en not_active Revoked
- 2007-12-21 HU HUE18157578A patent/HUE060822T2/hu unknown
- 2007-12-21 WO PCT/US2007/088542 patent/WO2009131553A2/en not_active Ceased
- 2007-12-21 PL PL18157578.8T patent/PL3345607T3/pl unknown
- 2007-12-21 JP JP2010509325A patent/JP2010528002A/ja not_active Withdrawn
- 2007-12-21 SI SI200732194T patent/SI3345607T1/sl unknown
- 2007-12-21 ES ES18157578T patent/ES2930183T3/es active Active
- 2007-12-21 PT PT181575788T patent/PT3345607T/pt unknown
- 2007-12-21 ES ES07875255.7T patent/ES2666650T3/es active Active
- 2007-12-21 EP EP22200370.9A patent/EP4176884A1/en active Pending
- 2007-12-21 EP EP18157578.8A patent/EP3345607B1/en not_active Revoked
- 2007-12-21 LT LTEP18157578.8T patent/LT3345607T/lt unknown
- 2007-12-21 DK DK18157578.8T patent/DK3345607T3/da active
-
2012
- 2012-03-15 US US13/420,846 patent/US20120201815A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/796,530 patent/US8877196B2/en active Active
- 2013-12-11 JP JP2013255627A patent/JP2014074046A/ja not_active Withdrawn
-
2014
- 2014-10-02 US US14/504,544 patent/US20150086571A1/en not_active Abandoned
-
2016
- 2016-08-22 JP JP2016161654A patent/JP2017014263A/ja not_active Withdrawn
- 2016-09-19 US US15/269,022 patent/US11608373B2/en active Active
-
2018
- 2018-09-26 JP JP2018179643A patent/JP2018199725A/ja active Pending
-
2023
- 2023-03-20 US US18/123,569 patent/US11807681B2/en active Active
- 2023-06-21 US US18/339,147 patent/US11891438B2/en active Active
- 2023-12-29 US US18/401,117 patent/US20240360207A1/en not_active Abandoned
-
2025
- 2025-11-04 US US19/379,682 patent/US20260062470A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528002A5 (enExample) | ||
| Virdi et al. | Sclerostin antibody increases bone volume and enhances implant fixation in a rat model | |
| Herford et al. | Reconstruction of mandibular continuity defects with bone morphogenetic protein-2 (rhBMP-2) | |
| Vukicevic et al. | The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing | |
| ES2583002T3 (es) | Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea | |
| US12264187B2 (en) | Compositions and methods for targeted therapeutic delivery to bone | |
| US9610320B2 (en) | Surgical applications for BMP binding protein | |
| US20150232558A1 (en) | Stimulating bone formation by inhibition of cd28 co-stimulation | |
| AU2007338627B2 (en) | Surgical applications for BMP binding protein | |
| Tinsley et al. | Systemic administration of sclerostin antibody enhances bone morphogenetic protein-induced femoral defect repair in a rat model | |
| US9694047B2 (en) | Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP) | |
| Tao et al. | Combined treatment with parathyroid hormone (1–34) and beta-tricalcium phosphate had an additive effect on local bone formation in a rat defect model | |
| Cunningham et al. | Osseointegration of autograft versus osteogenic protein–1 in posterolateral spinal arthrodesis: emphasis on the comparative mechanisms of bone induction | |
| Tatsumi et al. | Effect of ageing on healing of bilateral mandibular condyle fractures in a rat model | |
| JP2008540328A (ja) | 脱灰骨基質（ｄｅｍｉｎｅｒａｌｉｚｅｄｂｏｎｅｍａｔｒｉｘ）の活性化抽出 | |
| Fini et al. | Bone remodeling, humoral networks and smart biomaterial technology for osteoporosis | |
| KR20160032125A (ko) | 골 이식편의 골형성 잠재력 강화 | |
| Vegger et al. | Systemic treatment with strontium ranelate does not influence the healing of femoral mid-shaft defects in rats | |
| Buma et al. | Changes in innervation of long bones after insertion of an implant: Immunocytochemical study in goats with antibodies to calcitonin gene‐related peptide and B‐50/GAP‐43 | |
| Lin et al. | Combined antisclerostin antibody and parathyroid hormone (1–34) synergistically enhance the healing of bone defects in ovariectomized rats | |
| Torres et al. | The salivary peptide histatin-1 enhances bone repair in vivo | |
| US20260061035A1 (en) | Methods of improving spinal fusion with abaloparatide | |
| Baral | Osseointegration of a Cementless Total Knee Arthroplasty in a Murine Model of Glucocorticoid Induced Osteoporosis | |
| Bobyn | Improving Outcomes in NF1 Spine Fusion | |
| Chen | Recombinant human morphogenetic protein: its future role in spinal fusions |